News
FDA, GSK and Drug Administration
Digest more
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
A two-drug regimen involving an experimental cancer immunotherapy from iTeos Therapeutics and GSK didn’t significantly delay tumor progression in a Phase 2 trial, leading the companies to end ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback